Opinion statement Carcinoid syndrome (CS) is a complex disorder caused by functional
neuroendocrine tumors (NETs). This debilitating disease is characterized by hyper-secretion …

Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in
patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs …

This review reports on the currently available medical treatment options for the control of
symptoms due to carcinoid syndrome in patients with neuroendocrine tumors. The efficacy …

Background: Carcinoid syndrome symptoms significantly reduce quality of life in patients
with neuroendocrine tumors. Evidence supporting the use of somatostatin analogues in …

Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine
tumors. Several treatment options are available to alleviate the hormonal symptoms, but …

Carcinoid syndrome, a paraneoplastic condition linked with the release of multiple humoral
factors, affects around 30-40% of patients with well-differentiated neuroendocrine tumours …

Patients with well-differentiated neuroendocrine tumours may develop carcinoid syndrome
(CS), which is characterised by flushing, abdominal cramps, diarrhoea, and bronchospasms …

Approximately 30-40% of patients with well-differentiated neuroendocrine tumors present
with carcinoid syndrome, which is a paraneoplastic syndrome associated with the secretion …

As clinical awareness increases, carcinoid is becoming increasingly identified, often at an
earlier stage in the course of the disease. However, many patients remain undiagnosed until …

discussion The therapeutic options for refractory carcinoid syndrome are limited. The
development of new targeted agents for the treatment of neuroendocrine tumors (NET) has …